• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Drug and defibrillator interactions.

作者信息

Carnes C A, Mehdirad A A, Nelson S D

机构信息

College of Pharmacy, The Ohio State University, Columbus 43210, USA.

出版信息

Pharmacotherapy. 1998 May-Jun;18(3):516-25.

PMID:9620103
Abstract

We reviewed the interactions of drugs and defibrillators, with emphasis on implantable cardioverter defibrillators. Articles were identified by searching MEDLINE from 1966 to the present; additional sources were identified from reference lists in these articles. Drugs have the potential for both beneficial and harmful interactions with electrical therapy. Beneficial interactions include reductions in the energy required to defibrillate the heart and in the occurrence of arrhythmia resulting in decreased shock frequency, prolonged device longevity, and improved patient comfort. Potentially harmful interactions include altering the detection of ventricular tachycardia; altering the pacing threshold, resulting in interference with bradycardia or antitachycardia pacing; development of incessant ventricular tachycardia; and increasing the energy required to defibrillate the heart. As the use of implantable cardioverter defibrillators increases, pharmacists should be aware of the potential for drug-device interactions.

摘要

相似文献

1
Drug and defibrillator interactions.
Pharmacotherapy. 1998 May-Jun;18(3):516-25.
2
Drug-implantable cardioverter-defibrillator interactions.
Expert Rev Cardiovasc Ther. 2010 Sep;8(9):1267-73. doi: 10.1586/erc.10.114.
3
Role of antiarrhythmic drugs in patients with implantable cardioverter defibrillators.抗心律失常药物在植入式心脏复律除颤器患者中的应用。
Europace. 2010 May;12(5):618-25. doi: 10.1093/europace/euq073. Epub 2010 Mar 19.
4
The Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial: rationale, design, results, clinical implications and lessons for future trials.双腔与VVI植入式心脏除颤器(DAVID)试验:原理、设计、结果、临床意义及对未来试验的启示
Card Electrophysiol Rev. 2003 Dec;7(4):468-72. doi: 10.1023/B:CEPR.0000023165.20987.b1.
5
Inductionless or limited shock testing is possible in most patients with implantable cardioverter- defibrillators/cardiac resynchronization therapy defibrillators: results of the multicenter ASSURE Study (Arrhythmia Single Shock Defibrillation Threshold Testing Versus Upper Limit of Vulnerability: Risk Reduction Evaluation With Implantable Cardioverter-Defibrillator Implantations).大多数植入式心脏复律除颤器/心脏再同步治疗除颤器患者可行无诱导或有限电击测试:多中心ASSURE研究(心律失常单次电击除颤阈值测试与易损性上限:植入式心脏复律除颤器植入的风险降低评估)结果
Circulation. 2007 May 8;115(18):2382-9. doi: 10.1161/CIRCULATIONAHA.106.663112. Epub 2007 Apr 30.
6
Implantable defibrillators and/or amiodarone: alternatives or complementary therapies.
Int J Clin Pract. 1998 Sep;52(6):425-8.
7
[Anti-arrhythmic drugs interaction and defibrillation threshold in patients with implantable cardioverter defibrillator].[植入式心脏复律除颤器患者抗心律失常药物相互作用与除颤阈值]
Arq Bras Cardiol. 2003 Mar;80(3):336-9.
8
Implantable cardioverter defibrillator therapy and the need for concomitant antiarrhythmic drugs.植入式心脏复律除颤器治疗与联用抗心律失常药物的必要性。
J Cardiovasc Pharmacol Ther. 2007 Sep;12(3):175-80. doi: 10.1177/1074248407305608.
9
Interactions between antiarrhythmic drugs and implantable cardioverter-defibrillators.抗心律失常药物与植入式心脏复律除颤器之间的相互作用。
Curr Opin Cardiol. 1996 Jan;11(1):2-8. doi: 10.1097/00001573-199601000-00002.
10
When your patient has an implantable cardioverter defibrillator.当你的患者植入了心脏复律除颤器时。
Am J Nurs. 1994 Mar;94(3):34-8; quiz 39.

引用本文的文献

1
Going Beyond Antiarrhythmic-Anticoagulant Drug Interactions: Considerations in the Complex Medicated Patient.超越抗心律失常药与抗凝药的药物相互作用:复杂用药患者的考量
J Innov Card Rhythm Manag. 2019 Mar 15;10(3):3561-3563. doi: 10.19102/icrm.2019.100301. eCollection 2019 Mar.
2
[Is the determination of the defibrillation threshold in patients with an implantable cardioverter-defibrillator still required?].[植入式心脏复律除颤器患者仍需测定除颤阈值吗?]
Herzschrittmacherther Elektrophysiol. 2011 Dec;22(4):209-13. doi: 10.1007/s00399-011-0150-1. Epub 2011 Nov 13.
3
Dysregulated sarcoplasmic reticulum calcium release: potential pharmacological target in cardiac disease.
肌浆网钙释放失调:心脏病的潜在药理学靶点。
Pharmacol Ther. 2008 Sep;119(3):340-54. doi: 10.1016/j.pharmthera.2008.06.002. Epub 2008 Jul 12.